128 related articles for article (PubMed ID: 2230875)
21. Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction.
Egorin MJ; Conley BA; Forrest A; Zuhowski EG; Sinibaldi V; Van Echo DA
Cancer Res; 1987 Nov; 47(22):6104-10. PubMed ID: 2959359
[TBL] [Abstract][Full Text] [Related]
22. Etoposide protein binding in cancer patients.
Liu B; Earl HM; Poole CJ; Dunn J; Kerr DJ
Cancer Chemother Pharmacol; 1995; 36(6):506-12. PubMed ID: 7554043
[TBL] [Abstract][Full Text] [Related]
23. Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study.
You B; Tranchand B; Girard P; Falandry C; Ribba B; Chabaud S; Souquet PJ; Court-Fortune I; Trillet-Lenoir V; Fournel C; Tod M; Freyer G
Lung Cancer; 2008 Nov; 62(2):261-72. PubMed ID: 18442869
[TBL] [Abstract][Full Text] [Related]
24. Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)--a very effective regimen with good patients' compliance for advanced gastric cancer.
Cheng AL; Yeh KH; Lin JT; Hsu C; Liu MY
Anticancer Res; 1998; 18(2B):1267-72. PubMed ID: 9615799
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas.
Kroschinsky FP; Friedrichsen K; Mueller J; Pursche S; Haenel M; Prondzinsky R; Ehninger G; Schleyer E
Cancer Chemother Pharmacol; 2008 Apr; 61(5):785-90. PubMed ID: 17579865
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors.
Kaul S; Igwemezie LN; Stewart DJ; Fields SZ; Kosty M; Levithan N; Bukowski R; Gandara D; Goss G; O'Dwyer P
J Clin Oncol; 1995 Nov; 13(11):2835-41. PubMed ID: 7595746
[TBL] [Abstract][Full Text] [Related]
27. Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation.
Rodman JH; Murry DJ; Madden T; Santana VM
J Clin Oncol; 1994 Nov; 12(11):2390-7. PubMed ID: 7964955
[TBL] [Abstract][Full Text] [Related]
28. Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction.
Schaaf LJ; Hammond LA; Tipping SJ; Goldberg RM; Goel R; Kuhn JG; Miller LL; Compton LD; Cisar LA; Elfring GL; Gruia G; McGovren JP; Pirotta N; Yin D; Sharma A; Duncan BA; Rothenberg ML
Clin Cancer Res; 2006 Jun; 12(12):3782-91. PubMed ID: 16778106
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic drug monitoring of 21-day oral etoposide in patients with advanced non-small cell lung cancer.
Miller AA; Tolley EA; Niell HB
Clin Cancer Res; 1998 Jul; 4(7):1705-10. PubMed ID: 9676845
[TBL] [Abstract][Full Text] [Related]
30. Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity.
Ratain MJ; Mick R; Schilsky RL; Vogelzang NJ; Berezin F
J Clin Oncol; 1991 Aug; 9(8):1480-6. PubMed ID: 2072147
[TBL] [Abstract][Full Text] [Related]
31. Etoposide added to weekly leucovorin (LV)/5-fluorouracil (5-FU) in LV/5-FU pre-treated patients with advanced colorectal cancer.
Tsavaris N; Kosmas C; Gennatas K; Vadiaka M; Paliaros P; Dimitrakopoulos A; Diamantis T; Tsipras H; Papastratis G
Med Sci Monit; 2002 Sep; 8(9):PI65-9. PubMed ID: 12218954
[TBL] [Abstract][Full Text] [Related]
32. Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation.
Lowis SP; Pearson AD; Newell DR; Cole M
Cancer Res; 1993 Oct; 53(20):4881-9. PubMed ID: 8402676
[TBL] [Abstract][Full Text] [Related]
33. Etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) in 5-FU+LV pre-treated patients with advanced colorectal cancer.
Tsavaris N; Kosmas C; Gennatas K; Vadiaka M; Skopelitis E; Xila V; Rokana S; Margaris E; Zografos G; Papastratis G; Kouraklis G
J Chemother; 2002 Aug; 14(4):406-11. PubMed ID: 12420860
[TBL] [Abstract][Full Text] [Related]
34. Hepatic and renal function with successful long-term support on a continuous flow left ventricular assist device.
Deo SV; Sharma V; Altarabsheh SE; Hasin T; Dillon J; Shah IK; Durham LA; Stulak JM; Daly RC; Joyce LD; Park SJ
Heart Lung Circ; 2014 Mar; 23(3):229-33. PubMed ID: 23992754
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
Wolf M; Havemann K; Holle R; Gropp C; Drings P; Hans K; Schroeder M; Heim M; Dommes M; Mende S
J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710
[TBL] [Abstract][Full Text] [Related]
36. Phase I/II and pharmacologic study of long-term continuous infusion etoposide combined with cisplatin in patients with advanced non-small-cell lung cancer.
Kunitoh H; Watanabe K
J Clin Oncol; 1994 Jan; 12(1):83-9. PubMed ID: 8270989
[TBL] [Abstract][Full Text] [Related]
37. Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide.
Zimm S; Cleary SM; Lucas WE; Weiss RJ; Markman M; Andrews PA; Schiefer MA; Kim S; Horton C; Howell SB
Cancer Res; 1987 Mar; 47(6):1712-6. PubMed ID: 3815369
[TBL] [Abstract][Full Text] [Related]
38. An evaluation method for nonlinear local disposition in rat liver and kidney.
Kato T; Yamaoka K; Takakura Y
Drug Metab Dispos; 2004 Feb; 32(2):230-4. PubMed ID: 14744945
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study.
Loehrer PJ; Ansari R; Gonin R; Monaco F; Fisher W; Sandler A; Einhorn LH
J Clin Oncol; 1995 Oct; 13(10):2594-9. PubMed ID: 7595712
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic study of trimetrexate in combination with cisplatin.
Hudes GR; LaCreta F; Walczak J; Tinsley P; Litwin S; Comis RL; O'Dwyer PJ
Cancer Res; 1991 Jun; 51(12):3080-7. PubMed ID: 1828188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
